Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/21/2017 | 01:51pm CET

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Entry into a Material Definitive Agreement

Item1.01 Entry into a Material Definitive Agreement.

On February20, 2017, Sarepta Therapeutics Inc. (the Company)
entered into an Asset Purchase Agreement (the Agreement) with
Gilead Sciences, Inc. (Gilead) to which the Company agreed to
sell its Rare Pediatric Disease Priority Review Voucher (PRV).
The PRV was awarded to the Company by the U.S. Food and Drug
Administration in connection with the approval of Exondys51
(eteplirsen) Injection for the treatment of Duchenne muscular
dystrophy in patients who have a confirmed mutation of the DMD
gene that is amenable to exon 51 skipping. In consideration for
the PRV, Gilead will pay the Company $125,000,000 upon closing of
the PRV purchase. Closing of the PRV purchase is subject to
customary conditions, including the expiration or termination of
the required waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976. The Agreement contains customary
representations, warranties and covenants.

The foregoing summary of the Agreement is qualified in its
entirety by the full text of the Agreement, a copy of which will
be filed as an exhibit, with certain portions subject to
confidential treatment request, to the Companys Quarterly Report
on Form10-Q for the quarter ended March31, 2017, and incorporated
herein by reference.

On February21, 2017, the Company also issued a press release
announcing its entry into the Agreement. A copy of the press
release is filed as Exhibit99.1 to this Current Report on Form8-K
and is incorporated by reference into this Item1.01.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1 Press Release dated February21, 2017 titled Sarepta
Therapeutics Agrees to Sale of Priority Review Voucher for
$125 Million.

About Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Recent Trading Information
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed its last trading session up +0.31 at 28.28 with 1,406,684 shares trading hands.

The post Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
02/21 SAREPTA THERAPEUTICS, INC. (NASDAQ : SRPT) Files An 8-K Entry into a Material De..
02/19 GILEAD SCIENCES : Price gouging of lifesaving drugs raises alarms, threatens bud..
02/16 GILEAD SCIENCES : to Present at the RBC Capital Markets 2017 Global Healthcare C..
02/16 GILEAD SCIENCES : New Antiretrovirals Data Have Been Reported by Researchers at ..
02/16 GILEAD SCIENCES : Receives Approval in Canada for ODEFSEY™ for the Treatme..
02/15 GILEAD SCIENCES : Announces 144-Week Data Evaluating Safety and Efficacy of Genv..
02/14 Gilead challenges GSK with strong HIV drug data
02/14 GILEAD SCIENCES : Presents New Phase 2 Data on Bictegravir, an Investigational I..
02/14 GILEAD SCIENCES : Announces Findings from New Preclinical Study Evaluating Novel..
02/10 CYTODYN INC. : (CYDY) PRO 140 – A Promising Entry in the Treatment of HIV
More news
Sector news : Bio Therapeutic Drugs
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 What Could Vemlidy Mean For Gilead?
02/21 GILEAD : The Catalyst We Were Waiting For?
02/21 Gilead Gets The Best Of Sarepta In $125M PRV Sale
02/21 Sarepta sells Priority Review Voucher for $125M; shares ahead 2% premarket
Advertisement
Financials ($)
Sales 2017 24 644 M
EBIT 2017 15 598 M
Net income 2017 10 931 M
Finance 2017 306 M
Yield 2017 3,09%
P/E ratio 2017 8,88
P/E ratio 2018 9,39
EV / Sales 2017 3,69x
EV / Sales 2018 3,89x
Capitalization 91 287 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,8 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-3.24%91 287
AMGEN, INC.18.42%127 509
CELGENE CORPORATION3.19%92 920
REGENERON PHARMACEUTIC..1.23%39 421
ACTELION LTD22.45%28 891
VERTEX PHARMACEUTICALS..17.48%21 467
More Results